Maged Shenouda

CIK: 0001658369

Transaction Breakdown

Open Market Buys (P)10 (83.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (16.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RLMD

RELMADA THERAPEUTICS, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

RLMD
RELMADA THERAPEUTICS, INC.
Sep 10, 2026
Purchase(P)
Direct
79.8K shares at avg. $4.25$339K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 9, 2026
Purchase(P)
Direct
120.2K shares at avg. $4.20$505K
RLMD
RELMADA THERAPEUTICS, INC.
Dec 15, 2025
Purchase(P)
Direct
11.7K shares at avg. $4.12$48K
RLMD
RELMADA THERAPEUTICS, INC.
Dec 12, 2025
Award(A)
Stock Appreciation Rights
Direct
828K shares-
RLMD
RELMADA THERAPEUTICS, INC.
Nov 5, 2025
Purchase(P)
Direct
500K shares at avg. $2.20$1.1M
RLMD
RELMADA THERAPEUTICS, INC.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
600K shares-
RLMD
RELMADA THERAPEUTICS, INC.
May 20, 2025
Purchase(P)
Direct
60K shares at avg. $0.52$31K
RLMD
RELMADA THERAPEUTICS, INC.
May 19, 2025
Purchase(P)
Direct
90K shares at avg. $0.49$44K
RLMD
RELMADA THERAPEUTICS, INC.
May 16, 2025
Purchase(P)
Direct
50K shares at avg. $0.44$22K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 11, 2024
Purchase(P)
Direct
24.1K shares at avg. $2.95$71K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 10, 2024
Purchase(P)
Direct
21.1K shares at avg. $2.73$58K
RLMD
RELMADA THERAPEUTICS, INC.
Sep 9, 2024
Purchase(P)
Direct
8.2K shares at avg. $2.55$21K

		Type	Shares	Price		Ownership
Sep 10, 2026	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	79,800	$4.25	$339,150	Direct
Sep 9, 2026	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	120,200	$4.20	$504,840	Direct
Dec 15, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	11,665	$4.12	$48,060	Direct
Dec 12, 2025	RLMD RELMADA THERAPEUTICS, INC.	Award(A) Stock Appreciation Rights	828,000	-	-	Direct
Nov 5, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	500,000	$2.20	$1,100,000	Direct
Jun 26, 2025	RLMD RELMADA THERAPEUTICS, INC.	Award(A) Stock Option (right to buy)	600,000	-	-	Direct
May 20, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	60,000	$0.52	$31,422	Direct
May 19, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	90,000	$0.49	$43,686	Direct
May 16, 2025	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	50,000	$0.44	$22,100	Direct
Sep 11, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	24,120	$2.95	$71,154	Direct
Sep 10, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	21,118	$2.73	$57,652	Direct
Sep 9, 2024	RLMD RELMADA THERAPEUTICS, INC.	Purchase(P)	8,194	$2.55	$20,895	Direct

1-12 of 12 transactions

About Shenouda Maged

Shenouda Maged (SEC CIK 0001658369) files insider reports with the SEC as Chief Financial Officer of RELMADA THERAPEUTICS, INC. (RLMD).

Signal8 holds 6 ownership filings by Shenouda Maged, all Form 4s, filed between Sep 11, 2024 and Sep 11, 2026. Those filings report 12 transactions, from Sep 9, 2024 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Shenouda Maged's filings is in CORAL GABLES, FL.

Recent filings by Shenouda Maged

Sep 10, 2026: Open-market purchase of RLMD shares (Form 4, code P).
Sep 9, 2026: Open-market purchase of RLMD shares (Form 4, code P).
Dec 15, 2025: Open-market purchase of RLMD shares (Form 4, code P).
Dec 12, 2025: Grant or award of RLMD derivative securities (Form 4, code A).
Nov 5, 2025: Open-market purchase of RLMD shares (Form 4, code P).

Other insiders filing for RELMADA THERAPEUTICS, INC. (RLMD)

TRAVERSA SERGIO, Chief Executive Officer
Ence Chuck, CA and CO
Fedeli Fabiana, Director
GLASSPOOL JOHN, Director
Kelly Paul Edward, Director
CASAMENTO CHARLES J, Director

How to read Form 4 transaction codes